Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia
Maria Karamita, Christopher Barnum, Wiebke Möbius, Malú G. Tansey, David E. Szymkowski, Hans Lassmann, Lesley Probert
Maria Karamita, Christopher Barnum, Wiebke Möbius, Malú G. Tansey, David E. Szymkowski, Hans Lassmann, Lesley Probert
View: Text | PDF
Research Article Therapeutics

Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia

  • Text
  • PDF
Abstract

Multiple sclerosis (MS) is an inflammatory CNS demyelinating disease in which remyelination largely fails. Transmembrane TNF (tmTNF) and TNF receptor 2 are important for remyelination in experimental MS models, but it is unknown whether soluble TNF (solTNF), a major proinflammatory factor, is involved in regeneration processes. Here, we investigated the specific contribution of solTNF to demyelination and remyelination in the cuprizone model. Treatment with XPro1595, a selective inhibitor of solTNF that crosses the intact blood-brain barrier (BBB), in cuprizone-fed mice did not prevent toxin-induced oligodendrocyte loss and demyelination, but it permitted profound early remyelination due to improved phagocytosis of myelin debris by CNS macrophages and prevented disease-associated decline in motor performance. The beneficial effects of XPro1595 were absent in TNF-deficient mice and replicated in tmTNF-knockin mice, showing that tmTNF is sufficient for the maintenance of myelin and neuroprotection. These findings demonstrate that solTNF inhibits remyelination and repair in a cuprizone demyelination model and suggest that local production of solTNF in the CNS might be one reason why remyelination fails in MS. These findings also suggest that disinhibition of remyelination by selective inhibitors of solTNF that cross the BBB might represent a promising approach for treatment in progressive MS.

Authors

Maria Karamita, Christopher Barnum, Wiebke Möbius, Malú G. Tansey, David E. Szymkowski, Hans Lassmann, Lesley Probert

×

Figure 7

Inhibition of soluble TNF increases the clearance of myelin debris by phagocytic CNS macrophages and the production of new myelin in demyelinated lesions.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of soluble TNF increases the clearance of myelin debris by ph...
(A) 2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) immunostaining of oligodendrocytes (OLG) (left column), proteolipid protein (PLP) immunostaining of myelin (right column, blue), and Mac3 immunostaining of CNS macrophages (right column, red) in coronal paraffin sections of corpus callosum from CPZ0 or CPZ-fed mice. At each time point, representative sections from vehicle-treated (CPZ3, CPZ4, CPZ5; upper rows) or XPro1595-treated (CPZ0, CPZ3, CPZ4, CPZ5; lower rows) mice are shown (n = 5 per group). PLP immunoreactivity is massively increased in degenerating myelin that has lost OLG support (CPZ3, CPZ4, CPZ5). Scale bars: 100 μM. (B) Total numbers of CNPase-immunoreactive OLG/field (×40) (bars, left axis), and CNPase-immunoreactive OLG with apoptotic nuclei/field, as detected by hematoxylin counterstaining of nuclei (×40) (curves, right axis). (C and D) Total numbers of Mac3-immunoreactive macrophages (Mφ)/field (×40) (C), and proportions of Mac3-immunoreactive macrophages containing PLP-immunoreactive myelin/field (×40) (D), in the callosum of the same mice represented in A. (E) Proportions of mouse macrophage cells containing myelin basic protein–immunoreactive (MBP-immunoreactive) myelin assayed in the absence or presence of XPro1595. Statistical significance after comparisons between groups by two-way ANOVA with Bonferroni’s test (B, C, and D), or pairwise comparisons at each time point by Student’s t test (E), is shown. *P < 0.05, **P < 0.01, ***P < 0.001, ##P < 0.01, ###P < 0.001. (B, D, and F) Asterisks denote statistical differences of each treatment group represented by bars with the same treatment group at the previous time point. Hash tags denote statistical differences of each treatment group represented on curves with the same treatment group at the previous time point. (A) Arrowheads show macrophages enlarged in insets (CPZ3), areas cleared of myelin debris (CPZ4), and new myelin (CPZ5).Circles show values for individual mice (B–E).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts